A new medicine is promising to address treatment of treatment resistant.
Relacorilant, it was found that the medication tested in a phase 3 rosella trial with Corcept Therapeutics in California, improves general survival and the progression of the disease when combined with a chemotherapy medication called NAB-Paclitaxel.
The Rosella essay, carried out in collaboration with the GOG Foundation, analyzed 381 patients worldwide, including the United States, Europe, South Korea, Brazil, Argentina, Canada and Australia, according to a press release.
AI detects ovarian cancer better than human experts in a new study
The great phase 3 study revealed a 30% reduction in the risk of disease progression in patients with platinum resistant ovary cancer, compared to those who have just dealt with the Paclitaxel NAB. (Some types of chemotherapy contain the platinum element).
Patients whose disease returns less than six months after receiving the therapy containing platinum has a “platinum resistant” disease, according to Corcept Therapeutics. (Istock)
The researchers also pointed out “significant improvement” in general survival with this drug combination.
According to the reports, the relationship, which is administered as an oral pill, was “well tolerated” by patients without major side effects.
“A 30% decrease in the risk of recurrence and a decrease in the risk of death of 31% is promising.”
The medicine is administered orally one day before, on the day of and one day after the NAB-Paclitaxel therapy, which is administered through infusion every week.
The findings will be presented at a medical conference at the end of this year, researchers say. The results of phase 2 were published in the Journal of Clinical Oncology in 2023.
The treatment of ovarian cancer on the rapid path for the approval of the FDA as chemotherapy alternatives arise: “we are progressing”
Ovary cancer is the fifth most common cause of cancer death in women and is the most fatal of gynecological cancers, according to the ovarian cancer research alliance.
Alexander B. Olawaiye, MD, Director of Gynecological Cancer Research at the Magee-Women Hospital at Pittsburgh University and principal researcher at the Rosella trial, discussed the results with Fox News Digital.
According to the reports, the relationship, which is administered as an oral pill, was “well tolerated” by patients without major side effects. (Istock)
Olawaiye echoed that this new agent is the “first of its kind” in the battle against cancers that do not have many treatment options.
“That is what makes the findings of this study really exciting, because it showed a very significant improvement in both progression -free survival and general survival,” he said.
Signs of ovarian cancer, symptoms, diagnosis and treatment options
The expert shared his gratitude to his research team, mentioning that “they never stopped trying” for women who undergo treatment.
“I want to congratulate women who are being treated for ovarian cancer, first, for helping us to make this trial and second, for the potential that we can now have another option in the block.”
Patients in the trial showed a 30% decrease in the risk of death, according to researchers. (Istock)
Dr. Brian Slomovitz, director of Gynecological Oncology and co -president of the Cancer Research Committee at the Mount Sinai Medical Center in Miami Beach, Florida, also commented on these findings in an interview with Fox News Digital.
“We know that ovary cancer is very, very difficult to treat, particularly in those patients who have a standard chemotherapy resistant disease,” he said.
“For a long time, we have been trying to find treatments that can help patients not only to maintain remote disease, but also to live longer. And most of the trials, unfortunately, have been negative.”
Click here to register in our health newsletter
Slomovitz, a member of the GOG Foundation, said that Rosella’s trial is an “opportunity to use a unique drug” that has shown “positive and encouraging results.”
“A 30% decrease in the risk of recurrence and a decrease in the risk of death of 31% is promising,” he said.
The Relacorilant is administered one day before, on the day of and one day after the NAB-Paclitaxel chemotherapy, which is administered through the infusion every week. (Istock)
“See data like this is refreshing, and represents something that is exciting for our patients suffering from ovarian cancer.”
Olawaiye shared his hope that the treatment would receive the clinical approval “very soon.”
For more health articles, visit www.foxnews.com/health
As research and technology advance, several cancer treatments have emerged in recent years.
Click here to get the Fox News application
Olawaiye commented that the last two decades have been a “very exciting moment”, since there has been an “explosion of approval” for cancer therapies.
“Today’s news about Relacorilant are just another addition,” he said.
